MVP Creation

Every startup begins the same way: a few smart people, a messy whiteboard, and a spark that feels bigger than the room you’re in. In the first weeks, you are not thinking about legal clauses. You are thinking about building. Shipping. Testing. Surviving. You are trying to turn an idea into something real. But here […]

Most founders think IP assignment is a “legal cleanup task.” Investors don’t. To an investor, your IP assignment structure answers one simple question: Does this company truly own what it sells? If the answer is unclear, even a strong product can become a risky deal. And in deep tech—AI, robotics, hardware, biotech-adjacent tools—risk around ownership

In BCI, the hardest work often happens before the first customer pays you. You spend months on data, signal quality, and “does it even work?” Then a lab, a big company, or a better-funded team sees the same thing and ships a version with a nicer case and a bigger press push. If your edge

If you are building an AI tool using open datasets, you are not alone. Most great AI products start that way. Open data is fast, cheap, and rich. But it also creates a real worry: “Can I even patent this if the data is public?” The answer is often yes—if you focus on the right

Most founders treat patents like a chore they’ll “do later.” Investors can tell. And it quietly hurts trust, even when the tech is strong. An IP roadmap fixes that. Not by turning you into a lawyer. Not by burying you in paperwork. But by giving you a clear, believable plan for how your ideas become

Open source can be one of the best growth moves a technical founder can make. It can bring users, trust, and a strong community faster than any ad spend ever will. But open source is also a one-way door. Once code is public, you cannot “unshare” what the world has already seen. And if you

If you are building a fast tech startup, you already feel the pull in two directions. One pull says: “Ship. Talk to users. Fix bugs. Move.”The other pull says: “Protect what we built before someone copies it.” Most founders think they must choose. They do not. You can build a patent portfolio without slowing down.

Every AI and machine learning startup has a moment where the team realizes something important: the model is not the moat. Your edge is usually a mix of things—how you collect data, how you clean it, how you train, how you ship, how you loop feedback back into the system, and how you make the

IP Considerations for Biotech and Life Sciences In biotech and life sciences, your work can be life-changing—and also easy to copy if you do not protect it early. A great assay, a new cell line, a cleaner manufacturing step, a smarter dosing method, a better biomarker, a novel delivery system… these are not “nice-to-haves.” They

If you build deep learning systems, you are building a factory made of code, data, and time. The model file you ship is only the tip of the iceberg. The real value often sits under the water: your training data, your labels, your feature pipeline, your prompts, your fine-tuning steps, your eval tests, and the